Pain Clinical Trial
Official title:
The Influence of Cardiovascular Autonomic Function on Endogenous Pain Modulation Before and After Exercise and Cognitive Task in Fibromyalgia
The study has three aims:
1. To investigate the influence of cardiovascular autonomic function on pain sensitivity at
rest in patients with fibromyalgia and age- and sex-matched controls
2. To investigate the influence of cardiovascular autonomic function at baseline and during
exercise on the pain response following submaximal isometric exercise
3. To study the relation between the pain response following physical and cognitive tasks
(exercise and mental math, respectively).
Status | Recruiting |
Enrollment | 250 |
Est. completion date | December 30, 2022 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Fibromyalgia - Healthy Controls without fibromyalgia - Stable medical management plan for four weeks prior to participation in the study. - Physical Activity Readiness Questionnaire - English proficiency Exclusion Criteria: - Elbow arthritis - Carpal tunnel syndrome - Cardiovascular disease - Cervical surgery - Cerebrovascular accident / stroke - Multiple sclerosis - Parkinson's disease - Any central neurodegenerative disease - Traumatic brain injury - Peripheral neuropathy of the upper extremity - Myocardial infarction - Chronic obstructive pulmonary disease - Any unstable medical or psychiatric condition - Diabetes mellitus - Active cancer - Lymphedema of the upper extremity - Claustrophobia - Raynaud's phenomenon - Osteoporosis - Major depressive disorder - Bipolar disorder - Rheumatoid arthritis - Lupus - Polymyalgia rheumatica - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Marquette University | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Marquette University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Pressure Pain Threshold to immediately after performance of exercise. | Application of a pressure stimulus to the right forearm and quadriceps muscle at a rate of 50kPa per second until the pressure first becomes painful. | Before and immediately after exercise at session 2 or 3 which is on day 7 or day 21. | |
Primary | Change from Baseline Pressure Pain Threshold to immediately after cognitive task. | Application of a pressure stimulus to the right forearm muscle and quadriceps muscle at a rate of 50kPa per second until the pressure first becomes painful. | Before and immediately after cognitive task at session 2 or 3 which is on day 7 or day 21. | |
Primary | Change from Baseline Pressure Pain Threshold to during the submersion of the foot in ice water. | Application of a pressure stimulus to the right forearm muscle and quadriceps muscle at a rate of 50kPa per second until the pressure first becomes painful. | Before and during the submersion of the foot in ice water on session 2 which is day 7 of data collection | |
Primary | Temporal summation of heat assessment. | Subjects will receive ten heat pulses with ramp and return rate of 8°C/second to the baseline temperature. The peak stimulus interval 0.6 second and the inter-stimulus interval is 0.3 seconds. The baseline temperature will be 39°C. Subjects will be asked to rate the first, third, fifth, eighth and tenth stimuli. | the beginning of session 3 which day 21 of data collection | |
Primary | Heart Rate Variability | Electrocardiogram data will be recorded for ten minutes. Subjects will be instructed to relax. A two-lead configuration method will be utilized with electrodes placed at right clavicle (negative electrode), left lower rib (positive electrode), and left clavicle (ground electrode). | baseline, session1 which is day 1 of data collection | |
Primary | Change in Heart Rate during Deep Breathing Test | The test is done by asking the participant to perform six breathing cycles with each cycle consists of a five seconds inhalation and 5 seconds exhalation (10 second-cycle). Subjects will perform practice trials until they perform respiratory cycles without sudden inhalation or exhalation or holding the breath. Continuous electrocardiogram data will be collected. The change of heart rate during deep breathing test reflects the cardiovascular parasympathetic function. Reduced heart rate variability during deep breathing test indicates reduced parasympathetic tone. | baseline, session 1 which is day 1 of data collection | |
Primary | Change in Blood Pressure during Valsalva Maneuver | Subjects will be instructed to perform a forceful expiration at a pressure of 40 mm Hg for 15 seconds. This is done by blowing into a syringe that is connected to a pressure gauge, which will be placed in front of the subjects for visual feedback. In addition, feedback of the time will be provided. Continuous blood pressure will be collected during the test. The recovery time of blood pressure to baseline after Valsalva reflects the cardiovascular sympathetic tone. Greater recovery time indicates reduced sympathetic tone. | baseline, session 1 which is day 1 of data collection | |
Secondary | Total time spent in sedentary and moderate to vigorous physical activity measured by an Actigraph over the course of 7 days. | An Actigraph is a waist worn device that is used to track the amount and intensity of physical activity performed over the course of seven days. Total time spent in sedentary and moderate to vigorous physical activity is measured in minutes. | Worn continuously for a 7-day period during study enrollment. | |
Secondary | Cortisol Awakening Response (CAR) | CAR represents the increase of cortisol levels after awakening particularly in the first 30-45 minutes post-awakening. CAR is normal circadian phenomenon and the increase of cortisol levels post-awakening can range from 50 -150% in healthy adults. CAR can be assessed by taking three samples following awakening (immediately post-awakening, 30 minutes and 45 post-awakening). Reduced CAR indicates a dysfunction in the hypothalamus-pituitary-adrenal axis and reduction in the ability to respond to acute or chronic physiological or psychological stress. | samples will be collected at home at any day between day 1 and day 7 of data collection | |
Secondary | Six-Minute Walk Test | Subjects will be asked to walk as fast as they can on a straight 30 meters walking course for six minutes. The start and end points will be marked with cones. After each minute, subjects will be informed of the time left and standardized encouragement will be provided. Subjects will be asked at the beginning, middle, and end of the test to rate their pain from 0 (no pain) to 10 (worst pain), and to rate their perceived exertion from 0 (nothing at all) to 10 (extremely strong). At the end of the six minutes, subjects will be asked to stop and the distance walked will be measured. | time frame: baseline, day 1 of data collection | |
Secondary | The Fibromyalgia Impact Questionnaire - Revised | This questionnaire evaluates the severity of fibromyalgia symptoms over the past 7 days. It has three domains: symptoms, overall impact, and function. The total score ranges from a minimum of 0 to maximum of 210 with higher scores indicating worse function and symptoms. | on session 1, 2 and 3 which are on day 1,7 and 21 of data collection. | |
Secondary | The Short-Form McGill Pain Questionnaire | This questionnaire will be used to evaluate the current clinical pain. It evaluates different aspect of pain such as affective, sensory, and cognitive aspects The total score ranges from a minimum of 0 to maximum 45 with higher scores indicating worse symptoms. | on session 1, 2 and 3 which are on day 1,7 and 21 of data collection | |
Secondary | Pain Catastrophizing Scale | This is a 13-item scale that evaluates if the subject has an exaggerated negative mental set towards pain. It has 3 sub-scales which are magnification, rumination, and helplessness. Greater scores indicate greater catastrophizing thinking. Rumination scale ranges from 0 to 16 with higher score indicating higher levels of rumination. Magnification scale ranges from 0 to 12 with higher scores indicating higher levels of magnification. Helplessness scale ranges from 0 to 24 with higher scores indicating higher levels of helplessness. The subscale scores are summed to compute a total score ranging from 0 to 52 with higher scores indicating higher levels of pain catastrophizing. | on session 1 which is day 1 of data collection. | |
Secondary | American College of Rheumatology Diagnostic Criteria for Fibromyalgia | This questionnaire characterizes the symptoms of those with fibromyalgia. The scale is composed of 3 subscales; widespread pain index, symptom severity score A and B. The widespread pain index ranges from 0 to 19 with 19 indicating greater number of body areas in which pain was experienced. The symptom severity score A ranges from 0 to 9 with 9 indicating greater symptom severity. The symptom severity score B ranges from 0 to 3 with 3 indicating greater number of symptoms experienced. The total Symptom Severity Score is calculated by adding symptom severity score A and symptom severity score B with a total range of 0 (no symptoms) to 12 (great deal of symptoms). | Day 1 of data collection | |
Secondary | Baseline Lean Mass | Measurement of lean mass with use of dual energy x-ray absorptiometry testing. | 7 days after enrollment. | |
Secondary | Baseline Fat Mass | Measurement of fat mass with use of dual energy x-ray absorptiometry testing. | 7 days after enrollment. | |
Secondary | Composite Autonomic Symptom Score | This is a 31-item questionnaire that evaluates 6 domains of autonomic nervous system which are secretomotor, orthostatic intolerance, vasomotor, bladder function, gastrointestinal, and pupillomotor. The score ranges from 0 to 100 with higher scores indicating worse autonomic function. | baseline, session1 which is day 1 of data collection | |
Secondary | Situational Pain Catastrophizing Scale | A 6-item questionnaire that explores the negative mental set or catastrophizing thinking in reference to a particular experimental pain experience. The scores ranges from 0 to 24 with higher scores indicating greater situational catastrophizing. | in session 2 and 3 which are day 7 and 21 of data collection | |
Secondary | Pain Anxiety Symptom Scale | This is a 20-item scale that evaluates the pain-related fear or anxiety. It has four domains: cognitive anxiety, avoidance, fearful thinking, and physiological anxiety. The scores range from 0 to 100. The higher the score, the greater the pain-related anxiety. | session 3 which is day 21 of data collection | |
Secondary | Depression Anxiety and Stress Scale (DASS21) | The DASS21 is a questionnaire that evaluates the overall psychological distress. It has three main subscales: depression, anxiety and stress subscale, and each subscale has 7 items. The DASS21 has been validated in chronic pain patients and non-clinical sample. In patients with FM, DASS21 is associated with the severity of symptoms measured with FIQR, and it mediates the relation between pain intensity and disability in patients with chronic low back pain. The scale has three subscales which are depression, anxiety and stress. The score of depression subscale ranges from 0 - 27. The score of anxiety ranges from 0 - 21. The score of stress ranges from 0 - 42. The greater the score in all subscales the worse the outcome. | session 3 which is day 21 of data collection | |
Secondary | State Version of State-Trait Anxiety Inventory | This is a 20-item questionnaire that evaluates different feelings the subject may or may not have at the moment. The score ranges from 0 to 80 with higher scores indicating greater state anxiety. | on session 1, 2 and 3 which are on day 1,7 and 21 of data collection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|